



Syddansk Universitet

Prenatal exposure to antifungal medication may change anogenital distance in male offspring

Mogensen, Djamilla Madelung; Pihl, Maria Bergkvist; Skakkebæk, Niels E.; Andersen, Helle Raun; Juul, Anders; Kyhl, Henriette Boye; Swan, Shanna; Kristensen, David Møbjerg Boslev; Andersen, Marianne; Lind, Dorte Vesterholm; Jensen, Tina Kold

Published in:

Environmental Health: A Global Access Science Source

DOI:

[10.1186/s12940-017-0263-z](https://doi.org/10.1186/s12940-017-0263-z)

Publication date:

2017

Document version

Publisher's PDF, also known as Version of record

Document license

CC0

Citation for pulished version (APA):

Mogensen, D. M., Pihl, M. B., Skakkebæk, N. E., Andersen, H. R., Juul, A., Kyhl, H. B., ... Jensen, T. K. (2017). Prenatal exposure to antifungal medication may change anogenital distance in male offspring: a preliminary study. *Environmental Health: A Global Access Science Source*, 16, [68]. DOI: 10.1186/s12940-017-0263-z

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 05. Jul. 2017

RESEARCH

Open Access



Prenatal exposure to antifungal medication may change anogenital distance in male offspring: a preliminary study

Djamilla Madelung Mogensen^{1†}, Maria Bergkvist Pihl^{1†}, Niels E. Skakkebak², Helle Raun Andersen¹, Anders Juul², Henriette Boye Kyhl^{3,4}, Shanna Swan⁵, David Møbjerg Kristensen⁶, Marianne Skovager Andersen⁷, Dorte Vesterholm Lind¹ and Tina Kold Jensen^{1,2,3*}

Abstract

Background: Vaginal candidiasis is frequent among pregnant women and it is treated with anti-fungal medication (conazoles). Conazoles have anti-androgenic properties and prenatal exposure in rodents is associated with a shorter (less masculine) anogenital distance (AGD) in male offspring. To our knowledge this has never been studied in humans.

Method: In the Odense Child Cohort pregnant women residing in Odense municipality, Denmark, were recruited at gestational age 8–16 weeks between 2010 and 2012. Of the eligible 2421 mother-child pairs, 812 mother-son pairs were included. Questionnaire data on medicine use were collected in first and third trimester and physical examination at age 3 month was performed.

Ano-scrotal distance; measured from the centre of anus to the posterior base of scrotum (AGDas). Ano-cephalad distance; measured from the centre of anus to the cephalad insertion of the penis (AGDap) and penile width; measured at the base of the penis.

Results: Eighty seven women had used antifungal medicine during pregnancy. Maternal use of oral fluconazole ($n = 4$) was associated with a 6.4 mm shorter AGDas (95% CI: -11.9;-0.9) in the male offspring. Use of antifungal vaginal tablets ($n = 21$), was associated with a non-significantly shorter AGDas (-1.9 mm; 95% CI: -4.3; 0.5) whereas exposure to vaginal cream ($n = 23$) was not associated to AGDas. Use of antifungal medicine in the window of genital development between 8 and 14 weeks of gestation was associated with a larger reduction in AGDas than exposure outside this window. Antifungal medicine intake was not associated with AGDap and penil width.

Conclusion: Our preliminary findings prompted us to hypothesize that maternal use of conazole antifungal medication during pregnancy may affect the masculinization of male offspring. If confirmed, pregnant women should be advised to use antifungal medicine with caution.

Keywords: Anogenital distance, Prenatal exposure, Antifungal medicine, Endocrine disruptors

* Correspondence: Tkjensen@health.sdu.dk

[†]Equal contributors

¹Department of Environmental Medicine, Institute of Public Health, University of Southern Denmark, Winsloewsparken 17 2, 5000 Odense C, Denmark

²Department of Growth and Reproduction and EDMaRC, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Full list of author information is available at the end of the article



Background

In pregnancy, the prevalence of vaginal candidiasis is increased compared to those not pregnant [1]. Treatment is antifungal compounds administered locally or systemically depending on the severity of symptoms [2]. In Denmark, antifungal vaginal tablets and antifungal vaginal cream with either the active ingredients miconazole or clotrimazole (both imidazoles) are recommended as first treatment for vaginal candidiasis. Oral fluconazole (triazole) is only recommended for severe cases when the woman is pregnant [3–9]. Imidazole and triazole compounds are anti-mycotic through inhibition of a specific cytochrome P450 enzyme (CYP51) involved in fungal cell wall synthesis, [10, 11] but they are also known inhibitors of a range of other CYP enzymes including those involved in androgen biosynthesis [11, 12]. Accordingly, anti-androgenic properties have been demonstrated for several conazole fungicides [12, 13].

In pregnancy, hormonal changes increase the risk of vaginal candidiasis, [1, 14, 15] and as the fetus is particularly vulnerable to endocrine disruption, use of anti-fungal medication might affect development of the genitalia [16–18]. A recent Danish study among 1,405,663 pregnant women found an association between use of oral fluconazole during pregnancy and miscarriage [19]. Case reports have linked high-dose, long-term treatment with oral fluconazole during pregnancy to a pattern of skeletal and craniofacial birth defects seen in the offspring. This has raised concern regarding the safety of oral fluconazole use during pregnancy [20–23]. Other studies have examined the association between maternal use of anti-fungal medicine and malformations in the offspring, but no consistent associations have been found [14, 24, 25]. Subtle signs of anti-androgen action have not been studied in children whose mothers used anti-fungal medication during pregnancy.

Anogenital distance (AGD: distance from anus to genitals) is routinely used in animal toxicology studies and is a sensitive test of exposure of the male fetus to anti-androgenic agents [26–28]. In rodents, AGD has been shown to reflect the amount of androgen to which a male fetus is exposed in early development: in utero exposure to lower levels of androgens results in a shorter AGD, which is one marker of de-masculinisation [26, 28]. A vulnerable fetal masculinisation programming window (MPW) has been identified in rodent models in which androgens must act to masculinise the components of the reproductive tract and to allow the later complete development. This MPW has been identified in human to occur between gestation weeks 8–14 [29].

To our knowledge, no human studies have examined the association between maternal exposure to antifungal medicine and AGD in the male offspring. We therefore prospectively investigated the association between systemic

or local use of antifungal medicine during pregnancy and the subsequent AGD and penile width in the male offspring at 3 months of age in the Odense Child Cohort (OCC) study.

Methods

Newly pregnant women at gestational age 8–16 weeks residing in Odense Municipality, Denmark, between 2010 and 2012 were recruited: at a voluntary information meeting about ultrasound examinations; at their first antenatal midwife visit; or at their ultrasound examination at Odense University Hospital. All of the pregnant women in the study completed two questionnaires, one during the first and one during the third trimester [30]. Serum samples were collected twice and urine samples once during pregnancy and stored in freezers at the Odense Patient data Explorative Network (OPEN) [30]. The study was carried out in accordance with the Helsinki Declaration II and was approved by the Regional Scientific Ethical Committees for Southern Denmark (S-20090130).

Of the eligible population of 6707 pregnant women, 4017 women were informed about the study and 2421 live born singletons with birth register data participated in the study and are currently being followed up. Participants were better educated (high school +1 year or more) and more often of Danish origin than non-participants [30].

In the questionnaire administered during the first trimester, participants were asked whether they had taken any topical or systemic medications (both prescription and over the counter) and if so to provide the name, dose and gestational week/s of use of each named medication. In the second questionnaire (administered during the third trimester) the women were asked to state whether they had experienced specific diseases or symptoms (including vaginal candidiasis) during the last 3 months of pregnancy. Furthermore, the women were asked to state whether they had ever used any type of medication during their entire pregnancy. They were asked to note names of medication, doses, total number of days of use and in which gestational week(s) it was used.

The answers from both questionnaires were categorised into: overall use of any type of antifungal medicine during pregnancy; use of fluconazole oral tablets; use of antifungal vaginal tablets (including antifungal vaginal cream if used in combination with vaginal tablets); use of antifungal vaginal cream only; and unspecific use of antifungal medicine (women who had not specifically noted which type of antifungal medicine they had used). In addition, we categorised use of antifungal oral and vaginal tablets into exposure in and outside the MPW (gestation weeks 8–14).

Three months after the expected date of birth, regardless of actual gestational age at birth, the children were invited for a clinical examination, which included measurements of

length, weight and AGD. The two measurements of AGD, and the measurement of penile width were made using a Vernier caliper, which is the recommended instrument for AGD measurement [31]. The shorter AGD measurement was measured from the centre of anus to the posterior base of scrotum (AGDas) and the longer from the centre of anus to the cephalad insertion of the penis (AGDap). Penile width was measured at the base of the penis. All of these measurements were made three times and the arithmetic mean was calculated. Expert-trained technicians performed the examinations [30]. 13 boys had AGD measured by two examiners. The coefficient of variation (CV) was 3% for all the triplicate AGD measurements. Inter-examiner CV was respectively 4%, 3% and 4% for AGDas, AGDap and penile width indicating a high degree of consistency.

Statistical analysis


Use of antifungal medicine during pregnancy was categorized into: no use (reference group); fluconazole oral tablets; vaginal tablets; vaginal cream; and use of antifungal medicine of unspecified type. Differences in distributions of use of antifungal medicine according to population characteristics were assessed by chi-square.

Univariate associations between use of antifungal medicine during pregnancy, and AGD and penile width at 3-months of age, were examined. Multiple linear regressions were then used to adjust for potential confounding factors. AGD values vary with age and weight of the child, and because the clinical examination was scheduled to take place three months after expected date of birth we constructed a measure of 'post-conceptual age' defined as the sum of gestational age at birth (in days) and the age of the child at the AGD measurements (in days). Multiple regression analyses were thus adjusted for the post-conceptual age and individual weight-for-age standard deviation score (Z-score) [32]. We examined several potential confounding factors including maternal age, maternal body mass index, ethnicity, smoking, alcohol consumption as well as parity, socioeconomic status, gestational age at the 3-month examination and birth weight. None of these factors changed the estimated beta-coefficient more than 10% and were therefore excluded from the final models.

We evaluated the fit of the regression models by testing the residuals for normality and by inspecting the residual plots. All statistical analyses were conducted in STATA13. *P*-values were considered significant when they were <0.05, and 95% confidence intervals were calculated.

Results

A total of 2421 live born singletons with birth registry data were included in the original OCC dataset. After the initial exclusions, as shown in Fig. 1, the final dataset consisted of 812 mother-son pairs with measurements at



3 months of whom there were 795 AGDap measurements, 810 AGDas measurements and 802 measurements of penile width.

Pregnant women using anti-fungal medicine were more often of non-European origin and had a shorter gestational age, but there were no differences in age, parity, smoking habit, alcohol intake, BMI or birth weight (Table 1).

Of the overall study population of 812 mother-son pairs, 87 (11%) women had used antifungal medicine during pregnancy (Table 1) of whom 4 women had been treated with oral tablets containing fluconazole (a single dose of 150 mg) within the MPW. In addition, 21 women had used vaginal tablets containing 500 mg to 1200 mg miconazole or clotrimazole of whom 11 had used them in the MPW. Furthermore, of the 21 women who had used vaginal tablets, 11 had used only antifungal vaginal tablets and the other 10 had used them in combination with antifungal vaginal cream. There were 23 women who had only used antifungal vaginal cream

Table 1 Population characteristics of 812 mother/boy pairs included in the study according to antifungal medicine use in percent

	Population characteristics N = 812 (%)	No use of antifungal medicine N = 725	Use of some form of antifungal medicine N = 87
Maternal age (y)			
<25	72(9)	9	9
25–35	555(72)	71	80
>35	150(19)	20	11
BMI (kg/m ²)			
<18.5	24(3)	3	6
18.5–24.9	495(61)	61	58
25–29.9	187(23)	23	22
> = 30	105(12)	13	14
Maternal ethnicity			
European	602(95)	96*	88*
Non-European	32(5)	4*	12*
Maternal smoking			
No	772(97)	97	97
Yes	25(3)	3	3
Alcohol consumption			
No	565(91)	92	88
Yes	54(9)	8	12
Parity			
Nulliparous	447(55)	55	53
Multiparous	364(45)	45	47
Socio economic status ^a			
Low	17(3)	2	5
Intermediate	189(30)	31	27
High	418(67)	67	68
Gestational age (weeks) at birth			
<37	28(4)	4*	4*
37–40	538(68)	66*	79*
>40	231(29)	30*	18*
Birth weight (g)			
<2500 g	18(2)	3	0
2500–3999 g	604(76)	75	79
> = 4000 g	175(22)	22	21

*p-value < 0.05 calculated by chi-square test

^aLow = high school or less, Intermediate = high school +1–3 years further education, High = high school +4 years or more further education

(active ingredients miconazole or clotrimazole) and 39 women had used antifungal medicine but did not specify type (Table 2 and Additional file 1).

After adjustment for weight-adjusted z-score and post-conceptional age, boys prenatally exposed to oral fluconazole had a significantly shorter AGDAs (−6.4 mm; 95% CI: −11.9; −0.9) at their 3-month examination compared

to unexposed boys (Table 2, Figs. 2 and 3). In addition, maternal use of antifungal vaginal tablets containing miconazole or clotrimazole was marginally associated with a shorter AGDAs (−1.9 mm; 95% CI: −4.3; 0.5). Boys exposed to vaginal tablets containing either miconazole or clotrimazole in the MPW had shorter AGDAs than those exposed outside the MPW (Table 2). When dividing use of vaginal tablets into only use of vaginal tablets and vaginal tablet use in combination with cream, boys prenatally exposed to only vaginal tablets had shorter AGDAs than those prenatally exposed to a combination (Table 2).

An association was found between unspecific antifungal medicine use and penile width (−0.5 mm; 95%CI: −0.9; −0.1) but no association was seen for penile width and other exposure groups (see Additional file 1). No association was found between prenatal exposure to any antifungal medicine and AGDap.

Discussion

Four pregnant women taking fluconazole orally gave birth to boys with a significantly shorter AGDAs (−6.4 mm) than unexposed boys. In addition, maternal use of antifungal vaginal tablets containing miconazole or clotrimazole was associated with a shorter AGDAs, although not significantly, whereas use of the same compounds in the form of vaginal creams did not affect AGDAs. AGDap and penile width were not affected apart from a shorter penile width among boys to mothers with unspecific use, which was probably due to chance. Interestingly, use of antifungal medicine in the window of genital development between 8 and 14 weeks of gestation was associated with a larger reduction in AGDAs than exposure outside of this window. This is in accordance with the sensitivity of this window to the effects of prenatal anti-androgen exposure in rodent studies [27]. We acknowledge that our rather preliminary findings are based on four cases, but they are biologically plausible and of public health importance as up to 20% of pregnant women experience vaginal candidiasis. In addition, a 6.4 mm shorter AGD corresponds to a 20% decrease and may be of clinical importance as it has been associated with abnormal adult male reproduction [33, 34].

This is to our knowledge the first human study to examine the association between maternal exposure to antifungal medicine and AGD in the offspring. Our findings are biologically plausible, as conazole antifungals have known anti-androgenic properties, [12] and exposure to chemicals with anti-androgenic action (e.g. phthalates) have been associated with shorter AGD in several human studies [32, 35–38]. Rodent studies have shown that an impairment of androgen action within the MPW can result abnormal development and function of reproductive organs [27]. Hence, exposure to anti-androgenic chemicals, including conazole antifungals, during the MPW have resulted in

Table 2 Mean (SD) anogenital distance (AGDs) in mm in boys at three months according to maternal use of antifungal medicine in pregnancy. Beta values represent adjusted mean difference calculated from multiple linear regression (95% confidence intervals, 95% CI) in AGD in boys whose mothers used antifungal medicine in pregnancy, compared to non-users


	N	AGDas		
		Mean (SD) mm	β^a mm	95% CI
No antifungal medicine use (reference)	723	36.1 (5.7)	Reference	
Vaginal tablets ^b	21	35.0 (7.2)	-1.9	(-4.3; 0.5)
Only vaginal tablets ^c	11	33.5 (7.5)	-3.0	(-6.3; 0.3)
Vaginal tablets in combination with cream ^c	10	36.7 (6.8)	-0.7	(-4.1; 2.8)
Vaginal tablets <i>in</i> masculinisation programming window ^d	11	35.0 (8.1)	-2.2	(-5.5; 1.1)
Vaginal tablets <i>outside</i> the masculinisation programming window ^d	10	35.0 (6.4)	-1.6	(-5.0; 1.9)
Vaginal cream ^b only	23	35.9 (6.7)	0.1	(-2.3; 2.4)
Fluconazole oral tablets	4	28.7 (4.2) ^e	-6.4 ^e	(-11.9; -0.9) ^e
Use of antifungal medicine but type not specified	39	35.5 (6.5)	-0.9	(-2.7; 0.9)

^aAdjusted for age and z-score for weight^bActive ingredients miconazole or clotrimazole^cSub-analysis where antifungal vaginal tablet use ($N = 21$) has been divided into "only vaginal tablet use" and "vaginal tablet used in combination with cream"^dSub-analysis where antifungal vaginal tablet use ($N = 21$) has been divided into "Vaginal tablets *in* masculinization programming window" and "Vaginal tablets *outside* the masculinization programming window"^e $p < 0.05$ after the adjusted oral tablets

hypospadias, cryptorchidism and shortened AGD in rodent studies [26, 27].

Two large registry-based Danish studies found no association between oral intake of fluconazole during the first trimester and 15 different birth defects in the offspring [24, 25], however, they did not measure AGD. Similar findings have been reported in other smaller studies [14, 15, 24], which also studied hypospadias, but none of the studies measured AGD, which may be a more sensitive marker of prenatal exposure to anti-androgens [32].

The association between maternal use of antifungal vaginal tablets and AGD was weaker than among boys exposed to oral treatment. This may be due to less potent anti-androgenic action of miconazole and clotrimazole and/or lower exposure from vaginal tablets. The same reasoning may be used for the lack of effect of vaginal cream exposure on AGDas, as exposure levels from creams, is expected to be even lower. Miconazole in vaginal tablets have been demonstrated to be absorbed systemically [39]. Women using vaginal tablets without combination with antifungal vaginal cream typically used

**Fig. 2** Mm reduction of AGDas (and 95% confidence intervals) according to maternal use of antifungal medicine adjusted for age and z-score for weight from multiple linear regression




Fig. 3 Column scatterplot of AGDAs in mm among boys not prenatally exposed to antifungal medicine (green dots), boys prenatally exposed to antifungal vaginal tablets *outside* the MPW (red dots), boys prenatally exposed to antifungal vaginal tablets *in* the MPW (blue dots), and boys prenatally exposed to oral fluconazole (purple dots)

tablets containing higher doses of miconazole or clotrimazole than women who used both tablets and cream. Thus, the fetus may be exposed to a higher dose after use of vaginal tablets alone compared to the combined treatment of vaginal tablets and cream which was seen by a shorter ADGAs in this group.

Participation rate was 43% [30] and only 11% of the women reported use of antifungal medicine, which is lower than the estimated 20% of all pregnant women suffering vaginal candidiasis [14, 15]. This could be due to the fact that our study population was higher educated and therefore more aware of the importance of avoiding medication use during pregnancy. Information about use of antifungal medicine was self-reported which might have led to misclassification. This is, however, not likely to be associated with AGD as the women were unaware of this measure when answering the questionnaires leading to an underestimation of the association.

AGD measurements has acceptable intra- and inter-examiner reliability, but with large inter-individual variation in measurements especially in AGDap measured from the anus to the top of the cephalad insertion of the

penis. AGDap is therefore more dependent on the size of the child, introducing a higher inaccuracy of the measurement. Also, penile width is small and thus the same absolute measurement error is of relatively larger importance. Confounding by indication may explain our findings, as the overgrowth of *Candida albicans* organism may be associated with a reduction in AGD, rather than the use of antifungal medication. We adjusted for relevant confounders but we cannot exclude the possibility of residual confounding from for example co-exposure to other environmental chemicals, lifestyle or health behavior.

In male rodents, the shortened AGD persists into adulthood confirming that interference of androgenic activity permanently alters the reproductive tissues [29]. In cross-sectional studies among adult men, AGD has been shown to have a significant positive association with sperm count [34]. In fact, AGD is now considered part of the spectrum of male intrauterine testicular disruption called the testicular dysgenesis syndrome (TDS) [18]. Therefore, the observed reduction in AGD may have potential long-term consequences for male reproductive health.

Conclusion

Based on our findings that four pregnant women taking fluconazole orally gave birth to boys with a significantly shorter AGD we hypothesize that maternal use of anti-fungal medication may cause anti-androgenic effects. Further studies on maternal antifungal use during pregnancy are needed. In the interim, pregnant women should be advised to use antifungal medicine with caution.

Additional file

Additional file 1: Table S1. Use of antifungal vaginal tablets (active ingredients clotrimazole or miconazole) and oral fluconazole and in relation to anogenital distance (AGD_s, AGD_{ap}) and penile width measurements among 25 mother/boy pairs. **Table S2.** Mean (SD) penile width in mm in boys at three months according to maternal use of antifungal medicine in pregnancy. Beta values represent adjusted mean difference (95% confidence intervals, 95% CI) in penile width in boys whose mothers used antifungal medicine in pregnancy, and non-users. (DOCX 110 kb)

Abbreviations

AGD_{ap}: Anogenital distance measured from the centre of anus to the cephalic insertion of the penis; AGD_s: Anogenital distance measured from the centre of anus to the posterior base of scrotum; MPW: Masculinization programming window; OCC: Odense child cohort; TDS: Testicular dysgenesis syndrome

Acknowledgements

The technicians at Hans Christian Andersen's children's Hospital are acknowledged for their careful examination of the children.

Funding

This work was supported by the Danish Foundation for Scientific Innovation and Technology (09–067180), The Danish Research Council (4004-00352B_FSS), Ronald McDonald Children Foundation, K. A. Rohde's and wife's Foundation, Odense University Hospital and Region of Southern Denmark, Municipality of Odense, The Danish Council for Strategic Research, Program Commission on Health, Food and Welfare (2101–08-0058), Odense University Hospital Research Foundation and Odense Patient data Exploratory Network (OPEN).

Availability of data and materials

The dataset supporting the conclusions of this article is available by contacting Tina Kold Jensen.

Authors' contributions

DMM and MBP did data cleaning, performed the data analysis and interpretation and drafted the manuscript. TKJ and DVL provided assistance with data analysis and interpretation and revised and edited the manuscript. HBK was responsible for the overall data collection and revised and edited the manuscript. NES, HRA, AJ, SS, DMK and MSA assisted with interpretation and revised the manuscript. All authors read and approved the final manuscript.

Competing interests

No authors have any competing financial interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was carried out in accordance with the Helsinki Declaration II and was approved by the Regional Scientific Ethical Committees for Southern Denmark (S-20090130).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Environmental Medicine, Institute of Public Health, University of Southern Denmark, Winsloewsparken 17 2, 5000 Odense C, Denmark. ²Department of Growth and Reproduction and EDMaRC, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ³Hans Christian Andersen Children's Hospital, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark. ⁴Odense Patient data Exploratory Network (OPEN), Odense University Hospital, DK-5000 Odense, Denmark. ⁵Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁶Department of Biology, Laboratory of Genomics and Molecular Biomedicine, University of Copenhagen, DK-2100 Copenhagen, Denmark. ⁷Department of Endocrinology, Odense University Hospital, DK-5000 Odense, Denmark.

Received: 13 January 2017 Accepted: 22 May 2017

Published online: 21 June 2017

References

- Sobel JD. Vulvovaginal candidosis. *Lancet*. 2007;369(9577):1961–71. doi:10.1016/S0140-6736(07)60917-9.
- Soong D, Einarson A. Vaginal yeast infections during pregnancy. *Canadian family physician Medecin de famille canadien*. 2009;55(3):255–6. Epub 2009/03/14. PubMed PMID: 19282531; PubMed Central PMCID: PMC2654841
- Dansk LI. Fluconazol Pro medicin: Pro.medicin.dk; 2014 [cited 2015 03–02]. Available from: <http://pro.medicin.dk/Medicin/Praeparater/3095>.
- Dansk LI. Brentan Pro medicin: Pro.medicin.dk; 2014 [cited 2015 03–02]. Available from: <http://pro.medicin.dk/Medicin/Praeparater/4269>.
- Dansk LI. Brentacore Pro medicin: Pro.medicin.dk; 2014 [cited 2015 03–02]. Available from: <http://pro.medicin.dk/Medicin/Praeparater/355>.
- Dansk LI. Canesten Pro Medicin: Pro.medicin.dk; 2014 [cited 2015 03–02]. Available from: <http://pro.medicin.dk/Medicin/Praeparater/3718>.
- Dansk LI. Diflucan Pro Medicin: Pro.medicin.dk; 2014 [cited 2015 03–02]. Available from: <http://pro.medicin.dk/Medicin/Praeparater/1209>.
- Dansk LI. Canvag, vaginaltabletter og creme 100 mg+10 mg-g.doc Produktresumé.dk Lægemiddelstyrrelsen; 2014 [cited 2015 03–02]. Available from: <http://www.produktresume.dk/docshare/dsweb/ApplySimpleSearch>.
- Cottreau JM, Barr VO. A review of antiviral and antifungal use and safety during pregnancy. *Pharmacotherapy* 2016;36(6):668–678. Epub 2016/05/04. doi: 10.1002/phar.1764. PubMed.
- Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. *N Engl J Med* 1994; 330(4):263–272. Epub 1994/01/27. doi:10.1056/nejm199401273300407. PubMed.
- Zarn JA, Bruschweiler BJ, Schlatter JR. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. *Environ Health Perspect*. 2003;111(3):255–61. Epub 2003/03/04. PubMed PMID: 12611652; PubMed Central PMCID: PMC261241380.
- Kjaerstad MB, Taxvig C, Nellemann C, Vinggaard AM, Andersen HR. Endocrine disrupting effects in vitro of conazole antifungals used as pesticides and pharmaceuticals. *Reproductive toxicology* (Elmsford, NY). 2010;30(4):573–82. Epub 2010/08/17. doi:10.1016/j.reprotox.2010.07.009. PubMed
- Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. *J Clin Invest*. 1983;71(5):1495–9. Epub 1983/05/01. PubMed PMID: 6304148; PubMed Central PMCID: PMC26437014
- Carter TC, Druschel CM, Romitti PA, Bell EM, Werler MM, Mitchell AA. Antifungal drugs and the risk of selected birth defects. *Am J Obstet Gynecol*. 2008;198(2):191–e1–7. Epub 2008/01/30. doi:10.1016/j.ajog.2007.08.044. PubMed
- Pilms B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. *J Antimicrob Chemother* 2015; 70(1):14–22. Epub 2014/09/11. doi:10.1093/jac/dku355. PubMed.
- Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocr Rev*. 2009;30(4):293–342. Epub 2009/06/09. doi:10.1210/er.2009-0002. PubMed PMID: 19502515; PubMed Central PMCID: PMC2726844

17. Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. *J Steroid Biochem Mol Biol*. 2011; 127(3–5):204–15. Epub 2011/09/09. doi:10.1016/j.jsbmb.2011.08.007. PubMed PMID: 21899826; PubMed Central PMCID: PMC3220783
18. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson AM, Eisenberg ML, et al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. *Physiol Rev* 2016;96(1): 55–97. Epub 2015/11/20. doi:10.1152/physrev.00017.2015. PubMed.
19. Molgaard-Nielsen D, Svanstrom H, Melbye M, Hviid A, Pasternak B. Association between use of oral Fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. *JAMA* 2016; 315(1):58–67. Epub 2016/01/10. doi:10.1001/jama.2015.17844. PubMed.
20. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. *Am J Med Genet*. 1997; 72(3):253–6. Epub 1997/10/23 22:26. PubMed
21. Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. *Pediatr Infect Dis J* 1992; 11(12):1062–1064. Epub 1992/12/01. PubMed.
22. Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. *Birth Defects Res Part A Clin Mol Teratol* 2005; 73(11): 919–923. Epub 2005/11/03. doi:10.1002/bdra.20189. PubMed.
23. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. *Clin Infect Dis* 1996; 22(2): 336–340. Epub 1996/02/01. PubMed.
24. Norgaard M, Pedersen L, Gislum M, Erichsen R, Sogaard KK, Schonheyder HC, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. *J Antimicrob Chemother* 2008; 62(1): 172–176. Epub 2008/04/11. doi:10.1093/jac/dkn157. PubMed.
25. Molgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. *N Engl J Med* 2013; 369(9):830–839. Epub 2013/08/30. doi:10.1056/NEJMoa1301066. PubMed.
26. Macleod DJ, Sharpe RM, Welsh M, Fisker M, Scott HM, Hutchison GR, et al. Androgen action in the masculinization programming window and development of male reproductive organs. *Int J Androl* 2010; 33(2):279–287. Epub 2009/12/17. doi:10.1111/j.1365-2605.2009.01005.x. PubMed.
27. Welsh M, Saunders PT, Fisker M, Scott HM, Hutchison GR, Smith LB, et al. Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. *J Clin Invest*. 2008;118(4):1479–90. Epub 2008/03/15. doi:10.1172/jci34241. PubMed PMID: 18340380; PubMed Central PMCID: PMC2267017
28. Christiansen S, Scholze M, Dalgaard M, Vinggaard AM, Axelstad M, Kortenkamp A, et al. Synergistic disruption of external male sex organ development by a mixture of four Antiandrogens. *Environ Health Perspect*. 2009;117(12):1839–46. doi:10.1289/ehp.0900689. PubMed PMID: 20049201; PubMed Central PMCID: PMC2799456
29. Welsh M, Suzuki H, Yamada G. The masculinization programming window. *Endocr Dev* 2014; 27:17–27. Epub 2014/09/24. doi:10.1159/000363609. PubMed.
30. Kyhl HB, Jensen TK, Barington T, Buhl S, Norberg LA, Jorgensen JS, et al. The Odense child cohort: aims, design, and cohort profile. *Paediatr Perinat Epidemiol* 2015; 29(3):250–258. Epub 2015/03/11. doi:10.1111/ppe.12183. PubMed.
31. Arbuckle TE, Hauser R, Swan SH, Mao CS, Longnecker MP, Main KM, et al. Meeting report: measuring endocrine-sensitive endpoints within the first years of life. *Environ Health Perspect*. 2008;116(7):948–51. Epub 2008/07/17. doi:10.1289/ehp.11226. PubMed PMID: 18629319; PubMed Central PMCID: PMC2453165
32. Swan SH. Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. *Environ Res*. 2008;108(2): 177–84. Epub 2008/10/25. PubMed PMID: 18949837; PubMed Central PMCID: PMC2775531
33. Juul A, Almstrup K, Andersson AM, Jensen TK, Jorgensen N, Main KM, et al. Possible fetal determinants of male infertility. *Nat Rev Endocrinol* 2014; 10(9):553–562. Epub 2014/06/18. doi:10.1038/nrendo.2014.97. PubMed.
34. Mendiola J, Stahlhut RW, Jorgensen N, Liu F, Swan SH. Shorter anogenital distance predicts poorer semen quality in young men in Rochester, New York. *Environ Health Perspect*. 2011;119(7):958–63. Epub 2011/03/08. doi:10.1289/ehp.1103421. PubMed PMID: 21377950; PubMed Central PMCID: PMC3222997
35. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect*. 2005;113(8):1056–61. Epub 2005/08/05. PubMed PMID: 16079079; PubMed Central PMCID: PMC1280349
36. Swan SH, Sathyanarayana S, Barrett ES, Janssen S, Liu F, Nguyen RH, et al. First trimester phthalate exposure and anogenital distance in newborns. *Human reproduction (Oxford, England)*. 2015;30(4):963–72. Epub 2015/02/24. doi:10.1093/humrep/deu363. PubMed PMID: 25697839; PubMed Central PMCID: PMC4359397
37. Martina CA, Weiss B, Swan SH. Lifestyle behaviors associated with exposures to endocrine disruptors. *Neurotoxicology*. 2012;33(6):1427–33. Epub 2012/06/29. doi:10.1016/j.neuro.2012.05.016. PubMed PMID: 22739065; PubMed Central PMCID: PMC3641683
38. Bornehag CG, Carlstedt F, Jonsson BA, Lindh CH, Jensen TK, Bodin A, et al. Prenatal phthalate exposures and anogenital distance in Swedish boys. *Environ Health Perspect*. 2015;123(1):101–7. Epub 2014/10/30. doi:10.1289/ehp.1408163. PubMed PMID: 25353625; PubMed Central PMCID: PMC4286276
39. Kjaerstad MB, Nielsen F, Nohr-Jensen L, Zwisler S, Broesen K, Andersen HR. Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. *Eur J Clin Pharmacol* 2010; 66(12):1189–97. Epub 2010/10/07. doi:10.1007/s00228-010-0906-2. PubMed.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

